Over the last six months, Hologic has consistently outperformed the Zacks Categorized Medical Products industry. The company has exited fiscal 2016 on a solid note with both its top and bottom line comfortably beating the Zacks Consensus Estimate. The company’s promising guidance for 2017 also raises confidence. In the last six months the stock rallied 9.3%, compared to 5.6% loss of the Zacks Categorized Medical Products Industry.
New High Analysis: Tile Shop, Hologic, Citrix Systems Near Buy Points
Leave a Reply